Tuesday 12 November: 11:00–12:30, Hall B1, Georgia World Congress Center, Atlanta, USA
Presenter: Désirée van der Heijde, Leiden University Medical Center, the Netherlands
SELECT-AXIS 1 is a phase II/III double-blind, placebo-controlled study in which 187 patients with ankylosing spondylitis and an inadequate response to NSAIDs have been randomly assigned to receive the selective JAK1 inhibitor upadacitinib or placebo. The primary outcome is ASAS40 response after 14 weeks.
What our Advisory Board said:
The first data for upadacitinib, a new JAK inhibitor, in ankylosing spondylitis (AS) will show us whether there is a viable oral medication, with a different mode of action to previously approved biologics, that can treat AS.